

Corey A Siegel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3468318/publications.pdf>

Version: 2024-02-01

138
papers

6,516
citations

61984

43
h-index

71685

76
g-index

199
all docs

199
docs citations

199
times ranked

5869
citing authors

#	ARTICLE	IF	CITATIONS
1	ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2019, 114, 384-413.	0.4	933
2	Risk of Lymphoma Associated With Combination Anti-“Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 874-881.	4.4	459
3	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-“Severe Crohn-“s Disease: Results From the US VICTORY Consortium. American Journal of Gastroenterology, 2016, 111, 1147-1155.	0.4	257
4	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. Gastroenterology, 2015, 148, 344-354.e5.	1.3	226
5	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1655-1668.e3.	4.4	214
6	Management of Patients With Crohn-“s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	1.3	185
7	SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut, 2021, 70, 635-640.	12.1	173
8	Crohn-“s Disease Patients-“s Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy. Gastroenterology, 2007, 133, 769-779.	1.3	167
9	Risks of Serious Infection or Lymphoma With Anti-“Tumor Necrosis-“Factor Therapy for Pediatric Inflammatory Bowel Disease: A-“Systematic Review. Clinical Gastroenterology and Hepatology, 2014, 12, 1443-1451.	4.4	137
10	Risks and Benefits of Infliximab for the Treatment of Crohn-“s Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1017-1024.	4.4	130
11	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.4	119
12	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-“Tumor Necrosis Factor Therapy for Crohn-“s Disease: A Meta-analysis of Placebo-controlled Trials. Clinical Gastroenterology and Hepatology, 2015, 13, 2233-2240.e2.	4.4	109
13	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	12.1	108
14	Systematic review: monotherapy with antitumour necrosis factor ± agents versus combination therapy with an immunosuppressive for IBD. Gut, 2014, 63, 1843-1853.	12.1	106
15	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-“an International, Cross-disciplinary Consensus. Journal of Crohn's and Colitis, 2018, 12, 408-418.	1.3	102
16	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn-“s-“s Disease. Gastroenterology, 2018, 155, 687-695.e10.	1.3	93
17	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014-2025.	0.4	93
18	Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut, 2012, 61, 459-465.	12.1	91

#	ARTICLE	IF	CITATIONS
19	Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 570-577.	1.9	78
20	Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 30-38.	1.9	72
21	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1594-1602.	0.4	71
22	Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 245-251.	3.2	69
23	Patient Preferences for Surgical Versus Medical Therapy for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 103-114.	1.9	67
24	Challenges in IBD Research: Precision Medicine. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S31-S39.	1.9	67
25	Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1-6.	1.9	61
26	Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management. <i>Journal of Managed Care Pharmacy</i> , 2010, 16, 616-628.	2.2	61
27	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	4.4	60
28	The Impact of Ulcerative Colitis on Patients' Lives Compared to Other Chronic Diseases: A Patient Survey. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1044-1052.	2.3	57
29	Transforming Gastroenterology Care With Telemedicine. <i>Gastroenterology</i> , 2017, 152, 958-963.	1.3	57
30	Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2018, 155, 1008-1011.e8.	1.3	56
31	When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1658-1662.	1.9	51
32	Do Inflammatory Bowel Disease Therapies Cause Cancer?. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1306-1321.	1.9	51
33	Lymphoma risk in children and young adults with inflammatory bowel disease: Analysis of a large single-center cohort. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 838-843.	1.9	50
34	Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1678-1681.	1.9	50
35	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2461-2467.	1.9	50
36	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 669-681.	3.7	48

#	ARTICLE	IF	CITATIONS
37	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	4.4	48
38	Medical Marijuana for Digestive Disorders: High Time to Prescribe?. <i>American Journal of Gastroenterology</i> , 2015, 110, 208-214.	0.4	47
39	Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 1516-1523.	0.4	47
40	Risk factors for colorectal cancer in Crohn's colitis: A case-control study. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 491-496.	1.9	46
41	The Appropriateness of Concomitant Immunomodulators With Anti-Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 655-659.	4.4	46
42	Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 46-51.	4.4	45
43	Translating Improved Quality of Care Into an Improved Quality of Life for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 908-912.	4.4	45
44	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2526-2534.e9.	4.4	45
45	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	4.4	44
46	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	4.4	44
47	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	4.4	41
48	The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 525-541.	2.2	39
49	Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?. <i>Risk Analysis</i> , 2009, 29, 121-136.	2.7	38
50	Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1302-1309.	4.4	36
51	Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. <i>Digestive and Liver Disease</i> , 2010, 42, 777-784.	0.9	35
52	Fostering Collaboration Through Creation of an IBD Learning Health System. <i>American Journal of Gastroenterology</i> , 2017, 112, 406-408.	0.4	35
53	Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00128.	2.5	35
54	Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2636-2645.	2.3	34

#	ARTICLE	IF	CITATIONS
55	Systematic review: hepatosplenic Tâ€cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 527-533.	3.7	34
56	A Survey Study of Gastroenterologistsâ€™ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 191-197.	1.9	33
57	Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patientsâ€™ Perspectives on Shared Decision Making. <i>Patient</i> , 2016, 9, 79-89.	2.7	32
58	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	4.4	32
59	Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. <i>Gastroenterology</i> , 2022, 163, 204-221.	1.3	32
60	Challenges in IBD Research. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 677-682.	1.9	31
61	Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 940-947.	1.9	29
62	Patientâ€™s Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease. <i>Digestion</i> , 2009, 79, 30-35.	2.3	28
63	Decreased Antibody Responses to Ad26.COVS Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 161, 2041-2043.e1.	1.3	27
64	Making therapeutic decisions in inflammatory bowel disease: the role of patients. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 334-338.	2.3	26
65	Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2927-2936.	1.9	25
66	Lost in translation. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2168-2172.	1.9	24
67	A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1014-1020.	1.3	24
68	The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1687-1695.	1.9	23
69	Colorectal cancer in Crohnâ€™s colitis is comparable to sporadic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2016, 31, 973-982.	2.2	23
70	Defining Failure of Medical Therapy for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 74-77.	1.9	22
71	Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1261-1267.	4.4	22
72	Increasing Patient Activation Could Improve Outcomes for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2975-2978.	1.9	21

#	ARTICLE	IF	CITATIONS
73	Anti-Tumor Necrosis Factor- α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 441-456.	2.2	20
74	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. <i>Gastroenterology</i> , 2018, 154, 1201-1202.	1.3	20
75	A Web-based Multimedia Program Before Colonoscopy Increased Knowledge and Decreased Anxiety, Sedation Requirement, and Procedure Time. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 519-523.	2.2	19
76	Quality Improvement Initiatives in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2017, 19, 41.	2.5	18
77	Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care. <i>American Journal of Gastroenterology</i> , 2018, 113, 1440-1443.	0.4	18
78	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1443-1451.	1.9	18
79	Embracing the internet for progress in shared decision-making. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1579-1580.	1.9	17
80	Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 403-405.	4.4	17
81	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). <i>BMJ Open</i> , 2022, 12, e057656.	1.9	17
82	Prognosticating the Course of Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 395-404.	1.4	15
83	A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 955-963.	3.7	15
84	Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2645-2649.e4.	4.4	15
85	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 839-841.e2.	4.4	15
86	Systems-Based Strategies to Consider Treatment Costs in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1010-1014.	4.4	14
87	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e143-e145.	1.9	13
88	Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium. <i>Gastroenterology</i> , 2017, 152, S371.	1.3	12
89	Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2410-2418.	0.4	12
90	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	1.9	11

#	ARTICLE	IF	CITATIONS
91	A pilot feasibility trial of cognitive-behavioural therapy for insomnia in people with inflammatory bowel disease. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000805.	2.7	11
92	Patients Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 141-146.	1.9	10
93	Poor Sleep in Inflammatory Bowel Disease Is Reflective of Distinct Sleep Disorders. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3096-3107.	2.3	10
94	The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 35-53.	4.5	10
95	Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e15946.	4.3	9
96	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	4.4	9
97	An Office-Based, Point-of-Care Test Predicts Treatment Outcomes With Community-Based Pelvic Floor Physical Therapy in Patients With Chronic Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1082-1090.	4.4	9
98	Improving quality of care in IBD: A STEEEP challenge. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 134-136.	1.9	8
99	Placing Value on Telemedicine for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 382-383.	0.4	8
100	OUP accepted manuscript. <i>International Journal for Quality in Health Care</i> , 2021, 33, ii40-ii47.	1.8	8
101	A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15994.	1.0	8
102	Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor \pm Agents for Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 411-428.	2.2	7
103	IBD LIVE Case Series Case 3. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2958-2968.	1.9	7
104	Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?. <i>Current Pharmaceutical Design</i> , 2019, 25, 64-68.	1.9	7
105	What Options Do We Have for Induction Therapy for Crohn's Disease?. <i>Digestive Diseases</i> , 2010, 28, 543-547.	1.9	6
106	Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, 884-887.	1.3	5
107	Beyond disease activity to overall disease severity in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 624-626.	8.1	5
108	Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1499-1504.	1.3	5

#	ARTICLE	IF	CITATIONS
109	Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review. <i>Digestive Diseases and Sciences</i> , 2021, 66, 843-854.	2.3	5
110	IBD LIVE Case Series—Case 1. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1696-1701.	1.9	4
111	Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 933-939.	1.9	4
112	Mo1846 Delivering High Value IBD Care Through Telemedicine Visits. <i>Gastroenterology</i> , 2016, 150, S792.	1.3	4
113	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1829-1831.	4.4	4
114	Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	4
115	Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process. <i>Inflammatory Bowel Diseases</i> , 2021, , .	1.9	4
116	Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 379-388.	1.3	4
117	Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors. <i>Scandinavian Journal of Pain</i> , 2021, 21, 283-295.	1.3	4
118	Is the Hype of Medical Marijuana All Smoke and Mirrors?. <i>American Journal of Gastroenterology</i> , 2016, 111, 161-162.	0.4	3
119	De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. <i>GastroHep</i> , 2019, 1, 108-117.	0.6	3
120	Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach. <i>Current Drug Targets</i> , 2018, 19, 740-747.	2.1	3
121	Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn's Disease. <i>Crohn's & Colitis 360</i> , 2021, 3, .	1.1	3
122	Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2459-2464.	0.4	3
123	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.4	3
124	Hyperbaric Oxygen as Successful Monotherapy for a Severe Ulcerative Colitis Flare. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1474-1475.	1.9	3
125	Previous Cancer in a Patient with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	2
126	A qualitative inquiry into patients' perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases. <i>Quality of Life Research</i> , 2020, 29, 2403-2414.	3.1	2

#	ARTICLE	IF	CITATIONS
127	Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study. <i>Inflammatory Bowel Diseases</i> , 2021, , .	1.9	2
128	As if mothers don't have enough to worry about. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 146-147.	1.9	1
129	Risks and Side Effects of Medical Therapy. , 2019, , 125-132.		1
130	Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e137-e137.	1.9	1
131	Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection. <i>Crohn's & Colitis</i> 360, 2022, 4, .	1.1	1
132	Bidirectional Correlations Between Health Confidence and Inflammatory Bowel Disease Activity: A Nationwide Longitudinal Cohort Study. <i>Inflammatory Bowel Diseases</i> , 0, , .	1.9	1
133	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 914-915.	4.4	0
134	Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease. , 2018, , 101-112.		0
135	Identifying and Predicting the Goals and Concerns of Individuals with Inflammatory Bowel Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
136	Patient decision tools in inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2013, 9, 585-7.	0.1	0
137	Management of Inflammatory Bowel Disease With Telemedicine. <i>Gastroenterology and Hepatology</i> , 2020, 16, 526-528.	0.1	0
138	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	2.3	0